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Abstract 
Objective: This pilot study compared the pharmacologic treatment history and clinical 
outcomes observed in pediatric outpatients with psychiatric disorders exposed to drugs of 
abuse in utero to those of an age-, sex- and psychiatric disorder-matched, non-drug-exposed 
group.  
Methods: In this matched cohort study, medical records of children treated at an academic, 
child and adolescent psychiatry outpatient clinic were reviewed.  Children with caregiver-
reported history of prenatal drug exposure were compared to a non-drug-exposed control 
group being cared for by the same providers. Patients were rated with the Clinical Global 
Impressions –Severity scale (CGI-S) throughout treatment. The changes in pre- and post-
treatment CGI-S scores and the total number of medication trials were determined between 
groups. 
Results: The drug-exposed group (n=30) had a higher total number of lifetime medication 
trials compared to the non-drug-exposed group (n=28), and were taking significantly more 
total medications, at their final assessment. Unlike the non-drug-exposed group, the drug-
exposed group demonstrated a lack of clinical improvement.   
Conclusions: These results suggest that in utero drug-exposed children may be more 
treatment-refractory to or experience greater side effects from the pharmacologic treatment of 
psychiatric disorders than controls, although we cannot determine if early environment or 
drugs exposure drives these findings. 
3 
Introduction 
Despite public health and individual provider efforts to decrease substance use among 
pregnant women (Gilbert et al., 2007; Polen, Whitlock, Wisdom, Nygren, & Bougatsos, 
2008; Pomeroy & Steiker, 2012; Svikis & Reid-Quinones, 2003), recent data suggest this 
remains a widespread problem.  Among 15- to 44-year-old pregnant women, 4.4% reported 
current use of illicit drugs, 10.8% reported current alcohol use and 16.3% reported cigarette 
use within the past month (U.S. Department of Health and Human Services, 2011).   Drug 
and alcohol use in pregnancy is thought to be a significant contributor to the development of 
cognitive (Fried, Watkinson, & Gray, 1998; Jacobson, Jacobson, Sokol, Martier, & Ager, 
1993) and psychiatric impairment (Huestis & Choo, 2002; Nair, Black, Ackerman, Schuler, 
& Keane, 2008) in exposed offspring. In particular, prenatal drug exposure has been 
associated with antisocial/disruptive behavior, impulsivity, attention problems, aggression 
and anxiety (Irner, 2012; Minnes, Lang, & Singer, 2011; Williams & Ross, 2007). Children 
exposed to drugs of abuse during the prenatal period are also vulnerable to attachment 
failures (Goodman, Hans, & Cox, 1999; O'Connor, Kogan, & Findlay, 2002), maltreatment 
(Kelley, 1992; Smith & Test, 2002; Sun, Freese, & Fitzgerald, 2007) and the other sequelae 
of ongoing parental drug use (Bartu, Sharp, Ludlow, & Doherty, 2006; Smith & Test, 2002). 
Animal models suggest that the presence of drugs of abuse during the prenatal period may be 
neurotoxic (Carneiro et al., 2005; Friedman & Wang, 1998; Lidow & Song, 2001) and may 
disrupt neurotransmitter systems relevant to mechanisms of action of psychopharmacological 
treatments (Simansky & Kachelries, 1996). Results suggest that exposed animals self-
administer more of the drug they were exposed to prenatally, in addition to other drugs of 
abuse (Malanga & Kosofsky, 2003). Drug-exposed youth may experience atypical or 
ineffective responses to pharmacologic treatment, but there has been no research to date to 
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address this in humans.  The existing literature also fails to provide any guidance to clinicians 
regarding this commonly encountered presentation. 
In human brain imaging studies (mean age = 8.2 years), prenatal cocaine exposure has 
been associated with decreased volume in some subcortical regions, including regions with 
prominent dopamine innervation, such as the putamen (Bhat & Baraban, 1993), as well as 
decreased cortical volumes in the occipital and parietal lobes (Dow-Edwards et al., 2006; 
Lewis et al., 2004; Rivkin et al., 2008). With prenatal exposure to methamphetamine, 
volumetric imaging studies in children (mean age = 7.4 years) also found decreased 
subcortical volumes, particularly in the putamen, globus pallidus and hippocampus (Chang et 
al., 2004). In utero exposure to alcohol has been better studied and found to be associated 
with diffuse decreased cerebral and cerebellar volumes (mean age = 13 years) (Sowell et al., 
2001), especially in regions related to verbal learning and executive functioning (Bookstein, 
Streissguth, Sampson, Connor, & Barr, 2002; Sowell, et al., 2001). Thus, drugs of abuse 
during the prenatal period have been associated with neurobiological changes across cortical 
and subcortical regions in children, typically in the direction of abnormally small structural 
volumes.  Given these brain abnormalities, multiple neurotransmitter systems are likely 
affected by prenatal drug exposure. Therefore, we hypothesized that across classes, 
psychotropic medications may be less effective in individuals with prenatal drug exposure, 
given the potential impact across neurotransmitter systems.    
The purpose of this pilot study was to evaluate whether response to 
psychopharmacological treatment is less effective in children with prenatal drug exposure, 
compared to psychiatrically similar outpatients without a history of prenatal drug exposure.  
In addition, we sought to determine if any patterns of psychotropic medication administration 
exist that differentiate these two groups.  Finally, based on the suspected neurobiological 
impact of in utero drug exposure, we assessed if drug-exposed children were less responsive 
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to treatment with all classes of psychotropic medications, as evidenced by the total number of 
trials of medication initiated.   
Methods 
Sample 
This matched cohort pilot study consisted of an Institutional Review Board (IRB) 
approved review of outpatient psychiatric records of 58 children and adolescents seen at a 
Child and Adolescent Psychiatry Outpatient Clinic at an academic medical center. The in 
utero drug-exposed cohort was selected from children ages 3- to 18-years-old who were 
referred to study personnel by their treating psychiatrist at the study site because of reported 
prenatal drug exposure.  Their chart was reviewed by a research assistant blind to the study’s 
intent to ensure the following inclusion criteria: presence of DSM-IV-TR Axis I diagnosis 
(American Psychiatric Association (APA) 2000), current and past psychotropic medication 
treatment and a caregiver report of a history of prenatal maternal misuse of one or more of 
the following: opiates, benzodiazepines, tobacco, alcohol, marijuana, stimulants, or 
unspecified polydrug use. Only one individual with isolated tobacco exposure was included. 
Three sibling pairs were included in the drug-exposed group. The non-drug-exposed 
psychiatric control group was selected from 3- to 18-year-olds who were also treated in the 
same clinic.  A blinded research assistant, whose work was cross-checked for reliability, 
randomly selected charts from the entire clinic population under the clinical management of 
four psychiatrists by first matching for drug-exposure. Clinical information was collected 
from a three-year period. The subjects were then matched case-by-case for age, sex, 
psychiatric diagnoses (with the exception of reactive attachment disorder as discussed 
below), socioeconomic status (SES) and race. SES ratings (low, lower-middle, middle, or 
high) were a combination of health insurance and parental employment provided by the adult 
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accompanying the child to the appointment; a lower SES is coded with a lower score. Family 
status is coded as a child living with one biological parent, two biological parents, adopted, in 
foster care, or other, defined as anything outside of these classifications (e.g. living with 
grandparents or court-appointed guardians). Each chart was screened to ensure that the 
psychiatric controls did not have in utero drug exposure. From a review of non-psychotropic 
medications, the two groups were also matched on different physical health issues including 
asthma, allergies, epilepsy, and gastroesophageal reflux disease. Information on SES, family 
status, psychiatric diagnoses, previously used psychotropic medications, psychotropic 
medication changes throughout the study period and the psychotropic medications prescribed 
at each visit of the study period were collected and recorded.  For inclusion, all cases were in 
treatment at our center for a minimum of one month.  The study period was limited to 
three years. The last visit reported here indicates the last time point in which data was 
recorded, not necessarily the child’s last treatment visit. Clinicians were unaware of plans for 
the chart review at the time of clinical management.  
Measures 
DSM-IV-TR diagnoses were determined by the treating child and adolescent 
psychiatrist through routine clinical assessments. For this study, the following diagnostic 
categories were coded: attention-deficit/hyperactivity disorder (ADHD; includes the 
hyperactive, inattentive and combined subtypes), oppositional defiant disorder (ODD), 
conduct disorder, other disruptive behavior disorders (disruptive behavior disorder not 
otherwise specified (NOS), intermittent explosive disorder, and pyromania), pervasive 
developmental disorders (pervasive developmental disorder NOS, Asperger’s disorder, and 
autistic disorder), post-traumatic stress disorder (PTSD), reactive attachment disorder (RAD),  
anxiety disorders (generalized anxiety disorder, obsessive-compulsive disorder, and social 
anxiety disorder),  mood disorders (major depressive disorder, dysthymic disorder, mood 
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disorder NOS, bipolar disorder and depressive disorder NOS), mental retardation, learning 
disorders (reading and specific learning disorders with impairment in writing or mathematics, 
and undefined learning disorders) and communication disorders (phonological disorder, 
expressive language disorder, and mixed receptive-expressive language disorder). Children 
with other DSM-IV-TR diagnoses did not present by chance in this sample, but were not 
intentionally excluded. Participants with more than one diagnosis within the same 
category were noted to be a single case within that diagnostic category (see  “Number of 
Cases with the Following Diagnoses;” Table 1). 
The classes of drugs of abuse for in utero exposure were classified as opiates, 
benzodiazepines, tobacco, alcohol, marijuana, stimulants (cocaine and methamphetamine) 
and unspecified polydrug use.  Unspecified polydrug use includes a caregiver report that 
during pregnancy the biological mother used multiple unknown drugs.  
Psychotropic medications that subjects were identified to be prescribed were coded as 
the following: atypical antipsychotics (aripiprazole, olanzapine, quetiapine, risperidone, and 
ziprasidone), alpha agonists (clonidine, guanfacine, and guanfacine ER), antidepressants 
(bupropion hydrochloride, citalopram, fluoxetine, fluvoxamine, imipramine, mirtazapine, 
paroxetine, sertraline, trazodone) anti-manic agents (carbamazepine, lamotrigine, lithium, 
oxcarbamazepine, and valproate), stimulants (dexmethylphenidate, 
dextroamphetamine/amphetamine, lisdexamfetamine, methylphenidate, and 
methamphetamine), typical antipsychotics (fluphenazine, haloperidol, and thorazine), 
anticholinergics (benztropine, diphenhydramine, and hydroxyzine), and other medications 
(atomoxetine, buspirone, clonazepam,  melatonin, and molindone).   
For each subject, the clinician-rated Clinical Global Impression–Severity scale (CGI-
S) (Guy, National Institute of Mental Health (U.S.). Psychopharmacology Research Branch., 
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& Early Clinical Drug Evaluation Program., 1976) was used as a metric for the patient’s 
general clinical severity and was rated at each clinical encounter, coded as ordinal data on the 
following 7-point scale: 1 = Normal, not at all ill, 2 = Borderline mentally ill, 3 = Mildly ill, 4 
= Moderately ill, 5 = Markedly ill, 6 = Severely ill, and 7 = Among the most extremely ill 
patients.  We use change in CGI-S as a proxy for clinical improvement or decline.  
Additional study outcome measures were: the total number of individual medications 
(behavioral, psychiatric) used throughout treatment at the clinic, the total number of 
individual medications prescribed at the last clinic visit included in this study period, the total 
overall number of medications used in the subject’s lifetime up through the last visit, the total 
number of visits to the clinic, and the total number of individual medications in each 
medication class used during each subject’s lifetime. 
Data Analysis 
Statistical analyses were conducted using SPSS version 20.0 (Chicago, IL: IBM; 
2012). Independent samples t-tests were performed to compare groups on age, SES, number 
of psychiatric diagnoses and classes of the various psychiatric medications for the purposes 
of group matching. Chi-squared tests were performed to compare sex and race (Caucasian 
vs. non-Caucasian) between the two groups. Independent samples t-tests were also used to 
assess group differences on psychotropic medication-related outcomes.  These included: the 
total number of outpatient psychiatric visits, the number of months in treatment, the total 
number of all types of psychotropic medications the subjects were taking at clinic intake, the 
total number of different medications prescribed throughout the subject’s treatment course, 
the total number of medications prescribed at the final clinical assessment time point, the 
total number of psychotropic medications previously prescribed prior to presentation to our 
clinic or prescribed during treatment in our clinic, and the total number of medications 
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prescribed throughout the subject’s lifetime in each medication class.  An analysis of 
covariance (ANCOVA; covariates: RAD diagnosis and family status) was also performed for 
these same clinical outcomes to ensure that results were not impacted by group differences in 
RAD diagnosis and family status due to results mentioned below. Lastly, to evaluate 
differences between the intake visit and the last clinic visit, paired t-tests were performed for 
the drug-exposed and the non-drug-exposed groups separately for their initial and final CGI-
S scores, the total number of medications they were prescribed at the intake and final visits 
and the number of medications prescribed by drug class. Significant within-group differences 
were also compared between groups. A threshold of p<0.05 was used to determine statistical 
significance. Corrections for multiple statistical comparisons were not undertaken given the 
small sample size and exploratory nature of this study. 
Results 
Table 1 provides demographic and clinical characteristics of the participants and the 
number of participants exposed in utero to a particular class of drug of abuse.  The two 
groups were matched on age, gender, race, SES, and the number and types of psychiatric 
(except RAD) and medical diagnoses, as case-by-case matching in these variables was used 
to select the control group.  The groups differed on the prevalence of RAD and family status. 
RAD was significantly more prevalent among the drug-exposed participants, although it was 
diagnosed in only 5 drug-exposed children.  Regarding family status, more children in the 
drug-exposed group lived in a foster or adopted home. Additionally, four control group 
participants had either an unreported or unknown family status. The groups did not 
differ on baseline CGI-S scores (Table 2) or for the experience and training of the clinicians. 
Clinical Outcomes 
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The drug-exposed and non-drug-exposed groups were compared based on various a 
priori defined clinical outcomes, as presented in Table 2. The two groups differed 
significantly on three of these outcomes. First, youth in the drug-exposed group were 
prescribed a greater number of psychotropic medications throughout their lifetime (mean = 
5.87, standard deviation (SD) = 3.839) than the non-drug-exposed group (mean = 4.11, SD = 
2.485; p = 0.044; effect size: Cohen’s d effect size= 0.544).  Second, the drug-exposed 
participants were prescribed significantly more psychotropic medications (mean = 2.30, SD = 
1.264) at the last outpatient psychiatric clinic visit than the non-drug-exposed group (mean = 
1.64, SD = 0.870; p = 0.026; Cohen’s d = 0.608).  Third, the reported final CGI-S score was 
higher (more severely ill) in the drug-exposed group (mean = 4.14, SD = 0.803) than the non-
drug-exposed group (mean = 3.57, SD = 1.080; p = 0.033; Cohen’s d = 0.599).  CGI-S scores 
did not differ at baseline: drug-exposed group (mean = 4.32, SD = 0.670) and non-drug-
exposed group (mean = 4.00, SD = 1.000; p = 0.177; Cohen’s d = 0.376).  There were no 
differences between the two groups on the total number of outpatient psychiatric clinic visits 
or duration of treatment (during the study period), the total number of psychotropic 
medications prescribed during the initiation of treatment at the clinic, or the number of 
medications prescribed throughout the subjects’ lifetime, within each specific medication 
class. The results of the ANCOVA co-varying for RAD and family status were no different 
than the results of the independent samples t-tests presented in Table 2.  
Table 3 details the changes in clinical outcomes between the two groups from the 
intake visit to the final clinic visit included in this study. For the non-drug-exposed group, 
three significant within-group differences were found: (1) The CGI-S scores were 
significantly lower (improved) at the final visit (p = 0.015); (2) the total number of 
psychotropic medications prescribed at the final visit of the study was significantly greater 
than the number of psychotropic medications prescribed at the intake visit (p = 0.006); and 
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(3) the number of stimulants prescribed at the final visit was significantly greater than at 
intake (p = 0.001).  No differences were found for the number of atypical antipsychotics, 
alpha agonists, anti-manic agents, antidepressants, anticholinergics, or the other medication 
classes prescribed over the duration of treatment in the clinic. For the drug-exposed group, 
three significant within group differences were found:  (1) the total number of psychotropic 
medications prescribed at the final visit in this study was significantly greater than the 
number of psychotropic medications subjects were taking at the intake visit (p = 0.005); (2) 
the number of atypical antipsychotics prescribed at the final visit was significantly greater 
than at intake (p = 0.006); and (3) the number of stimulants prescribed at the final visit was 
significantly greater than at intake (p = 0.001).  There were no differences found for the CGI-
S scores or for other classes of medications.  Statistical analyses could not be performed on 
the difference in the number of subjects prescribed typical antipsychotics because the 
standard error of the difference was zero.     
Group differences in the clinical outcomes between the intake visit and final visit are 
presented in Table 4.  Only the four variables that showed significant within group 
differences were evaluated for between group differences. These variables include the CGI-S 
scale score, the total number of prescribed medications, atypical antipsychotics, and 
stimulants during treatment at the clinic. No significant differences were found among these 
variables in the between groups comparisons.  
Discussion 
This matched cohort pilot study was performed to gain a preliminary understanding of 
psychotropic medication use and response in children prenatally exposed to drugs of abuse. 
The primary finding in this study is that the total number of psychotropic medications 
prescribed throughout the lifetime of children with a history of in utero drug-exposure was 
significantly higher than reported in children without a history of in utero drug exposure. The 
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results suggest that children with in utero drug exposure may be more refractory to treatment 
with psychotropic medications than their non-drug-exposed peers.  Drug-exposed youth also 
appear to be less responsive to pharmacotherapy compared to non-drug-exposed youth, as 
evidenced by the lack of significant improvement in clinical severity ratings while being 
prescribed an increased number of medications across time. Finally, we found that atypical 
antipsychotics and stimulants are prescribed at an increasing rate throughout the treatment 
course for in utero drug-exposed children, while stimulants alone are prescribed at a higher 
rate throughout treatment in the non-drug-exposed group.  Overall, the magnitude of all 
measured clinical changes (initial vs. final visits) did not differ between groups. 
The primary finding in this study is that the total number of psychotropic medications 
prescribed throughout the lifetime of children with a history of in utero drug-exposure was 
significantly higher than reported in children without a history of in utero drug exposure. It 
may be that these differences are based on the lack of significant improvement in target 
behavioral symptoms with psychotropic medications, the occurrence of more adverse effects 
of treatment, or both. It is worth noting that the initial clinical severity scores and number of 
psychiatric diagnoses at baseline did not differ between groups, suggesting that the drug-
exposed group was not simply more psychiatrically impaired, thus requiring more complex 
psychopharmacology.   
In addition to more lifetime psychotropic medication trials, drug-exposed children 
were also prescribed a greater number of medications at the final visit, compared to non-
drug-exposed children. However, both groups were found to have more medications 
prescribed at the final visit than at the initial visit.  This indicates that there is a general 
tendency to prescribe more medications as a result of treatment in an outpatient psychiatric 
clinic.  We suspect that some clinically-relevant aspect of drug-exposed youth (i.e., refractory 
symptoms, adverse events) results in a larger number of individual medications prescribed 
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over time. The results indicate that, as a whole, drug-exposed children required more 
medications to help control their symptoms, supporting clinical anecdotes and our study 
hypothesis that medication regimens may be more complex in those with prenatal drug 
exposure. Given the diffuse changes to neurocircuitry resulting from in utero drug exposure, 
it is certainly plausible that receptor-level interactions with medications are abnormal and 
result in ineffective responses or adverse effects. Similarly, the CGI-S score was the same 
between the groups at intake, but different between the two groups at the final assessed visit, 
indicating that the non-drug-exposed group had less severe clinical impairment with 
pharmacological treatment over time. In addition, the drug-exposed group showed no 
significant change in symptom severity via the CGI-S score over time with medication 
treatment (mean = 0.179 CGI-S score improvement), whereas the non-drug-exposed did 
show significant CGI-S score improvement (mean = 0.435 CGI-S score improvement). 
Again, this finding underscores the notion that drug-exposed youth may be more refractory to 
treatments, although the magnitude of change across treatment was small for both groups and 
did not differ between the two groups.  
It was also found that prenatally drug-exposed children were prescribed more atypical 
antipsychotics over the course of treatment.  This difference was not observed across 
treatment for non-drug-exposed youth.  Similarly, both non-drug-exposed and drug-exposed 
youth were receiving stimulant medications more often at the end of the study period than at 
the beginning.  Combined, these findings raise the possibility that stimulants may be more 
helpful and/or better tolerated in these populations of children seeking outpatient psychiatric 
treatment, while atypical antipsychotics may be preferable in drug-exposed youth. 
Alternatively, clinicians may be moving to second- and third- line agents like atypicals due to 
lack of appreciable symptomatic improvement or tolerability with first line agents.  However, 
direct between group comparisons of prescription changes to these medication classes across 
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treatment did not reflect these differences. Additional research in a larger sample is warranted 
to address this difference in clinician prescribing practices, as it may reflect important 
differences between groups in regards to insight into medication use, trends, and tolerability.  
There are several limitations to this preliminary study. First, this study was designed 
to be a pilot evaluation of the relationships between pharmacotherapy and clinical responses 
in children exposed to drugs in utero, in order to guide future, larger-scale investigations in 
this area.  Thus, the small sample size is a notable limitation. However, given the 
understudied clinical population and the lack of any prior studies investigating these 
relationships, the study remains of value. Second, assessments were not structured and 
treatment was naturalistic, subject to the biases of each clinician, as clinicians were not 
blinded to prenatal drug exposures.  Differences in medication adherence and participation in 
counseling or therapy, for which this study did not have the infrastructure to monitor, could 
also be present. Third, exposure to in utero drugs was obtained only by the presenting 
caregiver’s report and is therefore subject to errors or bias.  In most cases, a biological parent 
was not the reporter, but when either biological parent accompanied the child to the clinic, 
there could have been an inclination by the parents to minimize or deny prenatal drug 
exposure, which could result in a drug-exposed subject being placed in the non-drug-exposed 
group. Similarly, we attempted to control for a number of confounding variables that could 
result in group differences, but, as the higher rates of RAD suggest, the drug-exposed youth 
were likely to be exposed to a range of challenges early in the child’s life that were different 
from those in the non-drug-exposed group, despite their similar DSM-IV-TR diagnoses. 
These early life experiences likely impact brain development differently (Forns et al., 2012; 
McLaughlin, Fox, Zeanah, & Nelson, 2011; Sheridan, Fox, Zeanah, McLaughlin, & Nelson, 
2012) as well as the development of psychopathology (Steinhausen, Mas, Ledermann, & 
Metzke, 2006), but to date, specific effects on psychopharmacologic responses have not been 
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reported. Additionally, the potential for confounding results based on maternal 
psychopathological differences, genetic or not, were not accounted for between the two 
groups. Thus, there may be reasons why some mothers are more likely to use drugs of abuse 
during pregnancy that confound the results. However, given that animal studies have been 
able to control for these differences and still find drug-induced neurobiological changes, 
further study is warranted.  Fourth, the genetic confound of including three sibling pairs in 
the drug-exposed group was not accounted for given the preliminary nature of the study. 
Lastly, as with most research involving human participants and prenatal drug exposure, drug 
use during pregnancy was heterogeneous and diverse. Thus, no conclusions about the clinical 
impact of specific types of drugs of abuse can be made.  
Conclusions 
Prenatal drug exposure is common among children in psychiatric treatment (Johnson 
& Leff, 1999), but the impact of this in utero drug exposure on response to psychotropic 
medication treatment has previously been unexplored. In our pilot matched cohort study, 
drug-exposed children appear to be prescribed more psychotropic medications over their 
lifetime, based upon the data collected over the three-year treatment period of our study. Yet 
despite more medication trials, the drug-exposed group did not appear to experience 
associated clinical improvement. The increased number of prescribed trials of second or third 
line agents, such as atypical antipsychotics, also suggests the presence of refractory 
symptoms. 
Animal models and human neuroimaging studies indicate that prenatal drug exposure 
does have long-term consequences on the neurobiological and behavioral development of 
children.  The results of this preliminary study indicate that this exposure can result in more 
challenging psychotropic medication management, and that these children may be less 
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responsive to medications and/or more vulnerable to adverse effects. Additional investigation 
is needed to validate these findings and to determine if certain classes of psychotropic 
medications may potentially be more effective and better tolerated in these children.  
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Table 1 
Demographics and Clinical Characteristics 
Drug-Exposed 
 (n=30) 
Non-Drug Exposed 
 (n=28) 
p-value 
Age (Mean and Standard Deviation, in years) 7.71 (3.077) 7.83 (3.715) 0.895 
Sex Male 23 (76.7%) 21 (75%) Χ2= 0.882 
Female 7 (23.3%) 7 (25%) 
Race Caucasian 24 (80.0%) 20 (71.4%) 
Χ2= 0.832 African-American 2 (6.7%) 2 (7.1%) 
Bi-Racial 4 (13.3%) 2 (7.1%) 
Unknown 0 (0.0%) 4 (14.2%) 
Socioeconomic Status (SES) 1.53 (0.819) 2.00 (1.018) 0.059 
Number of Cases with the Following Family Status: 
One biological parent in home 6 (20.0%) 11 (39.3%) 
Two biological parents in home 1 (3.3%) 12 (42.9%) 
Adopted 17 (56.7%) 0 (0%) 
Foster Child 4 (13.3%) 0 (0%) 
Other 2 (6.7%) 1 (3.6%) 
Number of Psychiatric Diagnoses 2.33 (1.061) 1.96 (1.071) 0.193 
Number of Cases with the Following Diagnoses: 
ADHD 21 (70.0%) 15 (53.6%) 0.204 
Oppositional Defiant Disorder 13 (43.3%) 10 (35.7%) 0.561 
Conduct Disorder 2 (6.7%) 1 (3.6%) 0.602 
Other Disruptive Behavior Disorders 3 (10.0%) 2 (7.1%) 0.705 
Autism Spectrum Disorders 5 (16.7%) 7 (25%) 0.443 
Post-Traumatic Stress Disorder 3 (10%) 1 (3.6%) 0.343 
Reactive Attachment Disorder 5 (16.7%) 0 (0%) 0.024* 
Anxiety Disorders 2 (6.7%) 7 (25.0%) 0.055 
Depressive Disorders 5 (16.7%) 4 (14.3%) 0.807 
Mental Retardation 2 (6.7%) 1 (3.6%) 0.602 
Learning Disorders 2 (6.7%) 1 (3.6%) 0.602 
Communication Disorders 6 (20.0%) 2 (7.1%) 0.161 
Number of In Utero Exposed Drugs Classes 2.47 (0.937) 0.00 (0.000) 0.000* 
Number of Cases with the Following In Utero Drug Exposure: 
Opiates 4 (13.3%) 
Benzodiazepines 3 (10.0%) 
Tobacco 13 (43.3%) 
Alcohol 17 (56.7%) 
Marijuana 9 (30.0%) 
Stimulants 18 (60.0%) 
Polydrug Use 10 (33.3%) 
Table 1: Mean (Standard Deviation) reported for age, socioeconomic status, number of 
psychiatric diagnoses, and number of classes of drug exposures for both groups.  Frequencies 
(percentage) also reported for number of children with each gender, race (comparison done on 
white vs. non-white), psychiatric diagnoses, and individual classes of drug exposures. P-
values for each variable are presented based on independent samples t-tests. Outcomes 
marked with * indicate a significant group difference. SES is a rating determined by a 
combination of health insurance and parental employment; lower SES is coded with a lower 
score. Levels were low (1), lower-middle (2), middle (3), and high (4). Family status was 
coded as one biological parent (1), two biological parents (2), adopted (3), foster (4), and 
other (5). Abbreviation: ADHD attention-deficit/hyperactivity disorder. 

Table 2 
Clinical Outcomes 
Drug-Exposed  
(n=30) 
Non-Drug Exposed 
(n=28) 
p-value 
Baseline CGI-S Score 4.32 (0.670) [3-6] 4.00 (1.000) [3-6] 0.177 
Final CGI-S Score 4.14 (0.803) [3-6] 3.57 (1.080) [1-6] 0.033* 
Total Number of Outpatient 
Psychiatric Visits 
6.50 (5.958) [1-
22] 
6.29 (3.430) [1-11] 0.869 
Duration of Treatment (months) 
During Study Period 
19.0(11.9) [1-36] 25.5 (11.2) [1-36] 0.06 
Number of Psychotropic 
Medications at Clinic Intake 
1.43 (1.357) [0-4] 1.14 (1.239) [0-4] 0.399 
Number of Psychotropic 
Medications Used Throughout 
Clinic Treatment 
3.53 (2.113) [1-8] 3.25 (1.756) [0-7] 0.582 
Number of Psychotropic 
Medications Prescribed at the 
Last Study Visit 
2.30 (1.264) [1-5] 1.64 (0.870) [0-4] 0.026* 
Number of Medications 
Prescribed  Throughout Lifetime 
5.87 (3.839) [1-
19] 
4.11 (2.485) [0-10] 0.044* 
Number of Atypical 
Antipsychotics Prescribed 
Throughout Lifetime 
1.30 (1.264) [0-4] 0.86 (1.380) [0-5] 0.207 
Number of Alpha Agonists 
Prescribed Throughout Lifetime 
0.83 (0.791) [0-2] 0.50 (0.638) [0-2] 0.084 
Number of Anti-Manic Agents 
Prescribed Throughout Lifetime 
0.50 (1.167) [0-5] 0.14 (0.448) [0-2] 0.135 
Number of Stimulants Prescribed 
Throughout Lifetime 
1.60 (1.453) [0-4] 1.36 (1.496) [0-5] 0.533 
Number of Antidepressants 
Prescribed Throughout Lifetime 
1.00 (1.083) [0-4] 0.64 (0.780) [0-2] 0.158 
Number of Typical Antipsychotics 
Prescribed Throughout Lifetime 
0.03 (0.183) [0-1] 0.04 (0.189) [0-1] 0.961 
Number of Anticholinergics 
Prescribed Throughout Lifetime 
0.17 (0.461) [0-2] 0.11 (0.315) [0-1] 0.571 
Number of Other Medications 
Prescribed Throughout Lifetime 
0.43 (0.568) [0-2] 0.46 (0.637) [0-2] 0.846 
Table 2: Mean (Standard Deviation) [Range] with p-values based on independent samples t-
tests. Treatment related outcomes marked with * are significantly different between groups. 
Table 3 
Within Group Clinical Differences between Baseline and Last Visit 
Drug-Exposed 
(Difference   p-value)  
Non-Drug Exposed 
(Difference  p-value) 
CGI-S 0.179 (0.612)      0.134 0.435 (0.788)      0.015* 
Total Number of Prescribed 
Medications 
0.867 (1.502)      0.005* 0.500 (0.882)      0.006* 
Atypical Antipsychotics 0.233 (0.430)      0.006* 0.071 (0.378)      0.326 
Alpha Agonists 0.100 (0.403)      0.184 0.143 (0.448)      0.103 
Anti-Manic Agents -0.100 (0.305)     0.083 -0.036 (0.189)     0.326 
Stimulants 0.400 (0.563)      0.001* 0.571 (0.790)       0.001* 
Antidepressants 0.167 (0.461)      0.057 0.036 (0.429)       0.663 
Typical Antipsychotics a a 
Anticholinergics 0.000 (0.263)      1.000 -0.071 (0.262)      0.161 
Other 0.033 (0.414)      0.662 -0.036 (0.429)      0.663 
Table 3: Mean (Standard Deviation) with p-values reported for within-group comparisons. 
Outcomes marked with * indicate a significant group difference.   
aCannot be calculated because the standard error of the difference is 0. 
Table 4 
Between Group Differences between Baseline and Last Visit 
Drug-Exposed vs Non-Drug 
Exposed 
p-value 
CGI-S 0.256 0.197 
Total Number of Prescribed 
Medications 
0.367 0.266 
Atypical Antipsychotics 0.162 0.135 
Stimulants 0.171 0.343 
Table 4: Mean Differences between drug-exposed and non-drug exposed groups, with p-
values. 
